Search Results

September 18, 2026

Patients share what it’s like to have wAIHA, a disease that causes the immune system to destroy red blood cells

Warm autoimmune hemolytic anemia is a rare, life-threatening disease that causes intense fatigue. Johnson & Johnson has a new therapy that targets the underlying drivers of the disease. Here, two patients—and Johnson & Johnson employees—share their journey, from symptoms and diagnosis to managing work and personal life.

Health & wellness

September 17, 2026

5 things we now know about prostate cancer

This disease is highly treatable if caught early—but in its earliest stages, prostate cancer often has no symptoms, allowing it to develop without detection. Learn more about this common cancer and how Johnson & Johnson is innovating across both early-stage and advanced disease.

Our company

September 15, 2026

Statement on the earthquakes in Colombia

Innovative Medicine

September 15, 2026

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026

Low rates of rash, blood clots and administration-related reactions were observed with subcutaneous treatment and prophylaxis Fewer than 1% of patients discontinued treatment due to treatment-related events at one year New findings from Johnson & Johnson build on the MARIPOSA survival benefit and strengthen evidence for RYBREVANT FASPRO plus LAZCLUZE as first-line treatment

Innovative Medicine

September 14, 2026

Johnson & Johnson’s 2026 Oncology Care Index Finds Community Oncologists Confident in AI’s Promise, but Practical Adoption Still Lags

• Reported AI adoption in oncology has increased from 19% of healthcare providers across all practice settings in 2025 to 49% of community oncologists specifically in 2026 • Meanwhile use of advanced tools like predictive models remains low, at just 19%, revealing a gap between adoption and deeper implementation

Innovation

September 14, 2026

Striving for a cure for multiple myeloma: What HCPs need to know

Jordan Schecter, M.D., leader of Johnson & Johnson’s end-to-end development strategy for multiple myeloma, shares insight on the evolving treatment landscape of this rare blood cancer.

Innovative Medicine

September 14, 2026

Johnson & Johnson’s RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer

RYBREVANT plus chemotherapy demonstrates durable benefit with a differentiated approach that dual-targets EGFR and MET Results mark significant progress for a patient population with poor outcomes and a historical five-year survival rate of just 8%

Innovative Medicine

September 11, 2026

New overall survival data and treatment experience improvements reinforce the impact of RYBREVANT® (amivantamab-vmjw)-based regimens in EGFR-mutated lung cancer at WCLC 2026

Presidential Symposium to feature final overall survival results for first-line RYBREVANT plus chemotherapy in EGFR exon 20 insertion-mutated NSCLC Additional findings show low rates of key treatment-related events with subcutaneous RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) and prophylactic strategies

September 10, 2026

Johnson & Johnson receives CE Marking for ACUVUE OASYS MAX Reusable Contact Lenses

New 2-week reusable contact lens brings advanced ACUVUE OASYS MAX technologies to deliver superior comfort and visual clarity to patients, even at day 14*†i Expands the ACUVUE OASYS MAX portfolio with an advanced option for reusable contact lens wearers Designed to meet the growing demand for lasting comfort and clear vision in today’s screen-intensive world *†1

Innovative Medicine

September 9, 2026

Johnson & Johnson presents new data at IMS 2026 highlighting its industry-leading multiple myeloma portfolio, with the goal of advancing the potential for cure

· 35+ abstracts demonstrate new findings across DARZALEX®, TECVAYLI® plus DARZALEX FASPRO®, CARVYKTI®, TALVEY®, and the investigational trispecific antibody ramantamig, highlighting the potential of early intervention with immune-based therapies to transform outcomes across the patient journey · With decades of leadership in multiple myeloma, Johnson & Johnson continues to drive innovation throughout the patient journey, from market-leading backbone therapies to next-generation immune-based approaches

Search Results

No Results

Search Results